MX9303023A - Composicion farmaceutica para tratar desordenes gastricos. - Google Patents

Composicion farmaceutica para tratar desordenes gastricos.

Info

Publication number
MX9303023A
MX9303023A MX9303023A MX9303023A MX9303023A MX 9303023 A MX9303023 A MX 9303023A MX 9303023 A MX9303023 A MX 9303023A MX 9303023 A MX9303023 A MX 9303023A MX 9303023 A MX9303023 A MX 9303023A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
gastric disorders
treat gastric
disorders
drug
Prior art date
Application number
MX9303023A
Other languages
English (en)
Inventor
Steven Poile
Mark Coke
John Edward O'mullane
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9303023A publication Critical patent/MX9303023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen las composiciones farmacéuticas que comprenden un complejo formado entre un antagonista del receptor H2 de la histamina y una resina de intercambio iónico, para el tratamiento de desordenes o transtornos gástricos cuyas composiciones mejoran el tiempo de residencia del fármaco dentro del estómago y promueven la absorción local mediante la liberación del fármaco a partir del complejo, de una manera controlada.
MX9303023A 1992-05-26 1993-05-24 Composicion farmaceutica para tratar desordenes gastricos. MX9303023A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929211148A GB9211148D0 (en) 1992-05-26 1992-05-26 Novel treatment

Publications (1)

Publication Number Publication Date
MX9303023A true MX9303023A (es) 1994-05-31

Family

ID=10716043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303023A MX9303023A (es) 1992-05-26 1993-05-24 Composicion farmaceutica para tratar desordenes gastricos.

Country Status (8)

Country Link
EP (1) EP0642340A1 (es)
JP (1) JPH07507293A (es)
CN (1) CN1086129A (es)
AU (1) AU4082793A (es)
CA (1) CA2136623A1 (es)
GB (1) GB9211148D0 (es)
MX (1) MX9303023A (es)
WO (1) WO1993024124A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
AU2912695A (en) * 1994-08-12 1996-03-07 Henry C Caldwell Oral compositions of h2-antagonists
DE9420259U1 (de) * 1994-12-17 1995-02-09 Röhm GmbH, 64293 Darmstadt Entbittertes Ranitidin-Präparat
JPH1171285A (ja) * 1997-06-30 1999-03-16 Chugai Pharmaceut Co Ltd スクラルファート含有組成物及びその製造方法
US6555137B1 (en) * 1997-06-30 2003-04-29 Chugai Seiyaku Kabushiki Kaisha Sucralfate-containing composition and process for the preparation thereof
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
WO2006061700A2 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Rapid disintegrating taste masked compositions and a process for its preparations
JP6627485B2 (ja) * 2015-01-28 2020-01-08 ライオン株式会社 ゲル組成物及びその製造方法
CN105617368A (zh) * 2016-03-10 2016-06-01 韩秀敏 一种用于治疗急性胃粘膜病变的药物组合物及其制备方法
JP2021014431A (ja) * 2019-07-12 2021-02-12 ライオン株式会社 粉体組成物、粉体組成物を含有する内服固形製剤及びその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR806M (es) * 1960-08-31 1960-09-18
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
CN1086129A (zh) 1994-05-04
JPH07507293A (ja) 1995-08-10
CA2136623A1 (en) 1993-12-09
WO1993024124A1 (en) 1993-12-09
AU4082793A (en) 1993-12-30
GB9211148D0 (en) 1992-07-08
EP0642340A1 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
MX9303023A (es) Composicion farmaceutica para tratar desordenes gastricos.
CR9842A (es) Composiciones de celecoxib
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
PT754176E (pt) Novos carbamatos e ureias como modificadores da resistencia a multiplas drogas
ES2126122T3 (es) Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.
CA2189916A1 (en) A new regime for paclitaxel in kaposi's sarcoma patients
KR930702000A (ko) 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
ES2188582T3 (es) El uso de ranitidina-citrato de bismuto en combinacion con claritromicina o claritromicina y tetraciclina en la fabricacion de un medicamento para tratar trastornos gastrointestinales.
EP0974363A4 (en) REMEDIES FOR ADDICTION
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
DK0479093T3 (da) Oligosaccharidderivater og deres anvendelse som lægemidler
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
NO953892L (no) Imidazolokinoksalinon-derivater som EAA-antagonister
DK0521057T3 (da) Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse
NO982863L (no) Nye forbindelser med analgetisk effekt
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff